Prix OrbusNeich Medical Group Holdings Limited (06929.HK)

OrbusNeich Medical Group Holdings Ltd. operates as an investment holding company. The company employs 1,432 full-time employees The company went IPO on 2022-12-23. The firm is engaged in the design, development, manufacture, distribution and sale of interventional medical devices for the treatment of coronary heart disease and peripheral vascular diseases. The firm's main products include percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) balloons. In addition, the Company's products also include semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation and specialty catheters. The firm mainly conducts its businesses in domestic and overseas markets.